ClinicalTrials.gov
ClinicalTrials.gov Menu

Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00005878
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : October 13, 2016
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing cancer in patients with Barrett's esophagus.

PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing cancer in patients who have Barrett's esophagus.


Condition or disease Intervention/treatment Phase
Esophageal Cancer Drug: celecoxib Phase 2

Detailed Description:

OBJECTIVES:

  • Determine the safety and efficacy of celecoxib for regression of Barrett's dysplasia in patients with low or high-grade dysplasia of the esophagus.

OUTLINE: This is a randomized, parallel, double-blind, placebo-controlled, multicenter study. Patients are stratified according to center and grade of dysplasia at baseline (low vs high). Patients are randomized to one of two treatment arms.

  • Arm I: Patients receive oral celecoxib twice daily for 48-96 weeks.
  • Arm II: Patients receive oral placebo as in arm I. Treatment continues in both arms in the absence of unacceptable toxicity or development of adenocarcinoma of the esophagus or cancer at other sites.

Patients are followed at 12 weeks.

PROJECTED ACCRUAL: A total of 200 patients (100 per arm) will be accrued for this study.


Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Masking: Double
Primary Purpose: Prevention
Official Title: Chemoprevention for Barrett's Esophagus Trial (CBET)
Study Start Date : July 2000
Actual Primary Completion Date : September 2005
Actual Study Completion Date : September 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Celecoxib

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 120 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed Barrett's dysplasia with specific information on the location (level) of the highest grade of dysplasia based on biopsy from baseline endoscopy

    • Short segment Barrett's esophagus must be sufficient area to allow for biopsy without complete resection
  • No presence of reflux esophagitis grades 2-4
  • No history of confirmed invasive carcinoma of the esophagus
  • No diagnosis of esophageal, gastric, pyloric channel, or duodenal ulceration of 1 cm or more in diameter within the past 30 days

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified

Hematopoietic:

  • Hemoglobin at least 9 g/dL
  • Platelet count greater than 125,000/mm^3
  • WBC greater than 3,000/mm^3
  • No significant bleeding disorder
  • No other abnormal hematopoietic laboratory test result that would preclude study

Hepatic:

  • PT/PTT no greater than 1.5 times upper limit of normal (ULN)
  • AST/ALT less than 1.5 times ULN
  • Alkaline phosphatase less than 1.5 times ULN
  • No chronic or acute hepatic disorder
  • No abnormal hepatic laboratory test result that would preclude study

Renal:

  • Creatinine no greater than 1.5 times ULN
  • No chronic or acute renal disorder
  • No other abnormal renal laboratory test result that would preclude study

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No prior or concurrent active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)
  • No other prior or concurrent curatively treated malignancy with a survival prognosis of less than 5 years
  • No hypersensitivity or adverse reaction to COX-2 inhibitors (e.g., celecoxib), sulfonamides, salicylates, or NSAIDs
  • No other significant medical, psychological, or psychosocial condition that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • Not specified

Endocrine therapy:

  • At least 6 months since prior regular (at least 2 weeks duration) oral or intravenous corticosteroids
  • At least 6 months since prior regular (at least 4 weeks duration) inhaled corticosteroids
  • No concurrent regular oral or intravenous corticosteroids
  • No concurrent regular inhaled corticosteroids
  • Concurrent corticosteroid nasal spray allowed

Radiotherapy:

  • At least 12 weeks since prior radiotherapy to the chest or upper abdomen

Surgery:

  • At least 3 months since prior surgery to the esophagus or stomach except hiatal hernia repair, fundoplication, vagotomy, or pyloroplasty
  • No prior complete mucosal resection using any technique
  • No concurrent resection of high-grade nodule

Other:

  • At least 30 days since prior chronic (at least 3 times a week for greater than 2 weeks) aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs) (i.e., greater than 100 mg/day)
  • No prior complete mucosal ablation using any technique
  • No prior treatment on this study
  • At least 30 days since prior investigational medication including shingles vaccine
  • No concurrent chronic NSAIDs or COX-2 inhibitors except low-dose aspirin (i.e., no greater than 100 mg/day)
  • No concurrent anticoagulants (e.g., heparin or warfarin)
  • No other concurrent investigational medication
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005878


Locations
United States, Arizona
Veterans Affairs Medical Center - Tucson
Tucson, Arizona, United States, 85723
United States, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-1781
United States, Illinois
Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
Hines, Illinois, United States, 60141
United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21231-2410
United States, Minnesota
Mayo Clinic Cancer Center
Rochester, Minnesota, United States, 55905
United States, New York
Herbert Irving Comprehensive Cancer Center
New York, New York, United States, 10032
United States, Ohio
Ireland Cancer Center
Cleveland, Ohio, United States, 44106
United States, Oregon
Veterans Affairs Medical Center - Portland
Portland, Oregon, United States, 97207
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
Investigators
Study Chair: Arlene A. Forastiere, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications of Results:

Responsible Party: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ClinicalTrials.gov Identifier: NCT00005878     History of Changes
Other Study ID Numbers: JHOC-J9932, CDR0000067917
P30CA006973 ( U.S. NIH Grant/Contract )
JHOC-J9932
JHOC-99061108
NCI-P00-0145
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: October 13, 2016
Last Verified: October 2016

Keywords provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins:
esophageal cancer

Additional relevant MeSH terms:
Esophageal Neoplasms
Barrett Esophagus
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Abnormalities
Celecoxib
 Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents